You were had, so you bet we're f'ing done. Read and weep,

New Post Public Reply Private Reply Replies (0) Message Board
Bhawks copytele #117958
226
You were had, so you bet we're f'ing done. Read and weep, that is If you can comprehend it and admit you screwed up.

Bayer executive’s comments misinterpreted in social media posts

By Reuters Fact Check

https://www.reuters.com/article/idUSL1N2YF1AI/

June 28, 20229:22 AM CDTUpdated 2 years ago

Remarks by Bayer executive Stefan Oelrich in 2021 have been shared on social media to spread the false allegation that COVID-19 mRNA vaccines are a form of gene therapy.


Contrary to claims online, Oelrich was highlighting the public’s acceptance of such technological innovation as an example of how people could potentially also accept the company’s gene and cell therapies.

“The CEO of Bayer basically stating that 95% of people wouldn’t have taken the mRna 'gene therapy' two years ago. People were TRICKED and intentionally LIED TO, which was why so many people did,” reads a tweet with the 41-seconds-long clip ( here ).

An iteration on Instagram stating Oelirich admitted “that the COVID-19 vaccine is in fact gene therapy,” has garnered at least 4,475 likes. ( here )
Other iterations can be found ( here )( here ) ( here )
THE CLIP

The clip dates from Oct. 24, 2021, during the opening ceremony of the World Health Summit 2021. The commentary highlighted online can be heard around timestamp 1:37:27 ( here ).

But Oelrich, member of Bayer AG’s Board of Management and head of the Pharmaceuticals Division ( here ), did not “admit” the mRNA shots are a form of gene therapy as claimed on social media.

Further context shows that he was instead speaking about how the acceptance of a biotech innovation like mRNA COVID-19 vaccines was an example of how cell and gene therapies, another biotech innovation, could be received by the public.

“And for us therefore, we are really taking that leap -- us as a company Bayer -- in cell and gene therapy, which to me is one of these examples, where we are really going to make a difference, hopefully, moving forward.”

“Ultimately the mRNA vaccines are an example for that cell and gene therapy. I always like to say, if we had surveyed two years ago in the public, ‘would you be willing to take gene or cell therapy and inject it into your body?,’ we would have probably had a 95% refusal rate. I think this pandemic has also opened many people’s eyes to innovation in the way that was maybe not possible before.”

Moments earlier, Oelrich discussed innovation in the biotech field. “We’ve seen the vaccines as the perfect example during this crisis, but innovations in the field of biotech also radically up-end our view on many other diseases, specially NCDs ( here ). We can now think of curing many of those diseases, not just treating symptoms as we think forward.” ( youtu.be/OJFKBritLlc?t=5771 )

Reuters has reported about the German company’s efforts on developing cell and gene therapy ( here ) ( here ).

THE SCIENCE

Reuters previously addressed false claims that mRNA COVID-19 vaccines are a form of gene therapy ( here) or that the vaccines alter the recipient’s DNA (here) (here) (here)

While mRNA vaccines by Pfizer/BioNTech and Moderna can be considered a genetic-based therapy, because they use genetic material, a piece of RNA based on SARS-CoV-2, to prompt an immune response in recipients (here), this is not the same as gene therapy, which is designed to permanently change
the body’s genetic makeup, experts have told Reuters.

“Gene therapy, in the classical sense, involves making deliberate changes to a patient’s DNA in order to treat or cure them. mRNA vaccines will not enter a cell’s nucleus that houses your DNA genome. There is zero risk of these vaccines integrating into our own genome or altering our genetic makeup,” Dr Adam Taylor, a virologist and research fellow at the Menzies Health Institute, Queensland, Griffith University, told Reuters in August 2021.

Unlike gene therapy (here) (here), mRNA vaccines are then “rapidly degraded” by the body, Taylor said.

More information about gene therapy and mRNA vaccines can be found (here) (here).

VERDICT

False. In this clip, Bayer executive Stefan Oelrich did not “admit” that mRNA COVID-19 vaccines are “in fact” gene therapy. He was highlighting the public’s acceptance of a technological innovation like mRNA COVID-19 vaccines as an example of how people could potentially also accept the company’s gene and cell therapies.

While mRNA vaccines do use genetic material, they are not designed to change the recipient’s genetic makeup and thus they are distinct from gene therapy.

This article was produced by the Reuters Fact Check team. Read more about our fact-checking work here .
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HOST's $50M Boost Fuels Avondale's Expansion

Updated Category News Views 0

Big Bucks for Avondale's Next Leap HOST isn't playing around with pocket change here. The company's coughing up a neat $50 million to propel Avondale Global Gateway into its next chapter. This investment means serious business—it’s cranking up capacity like a power plant on overdrive, laying down more rail, warehouse spaces, and dock improvements. A new...

Continue Reading
Medunik USA Ensures Steady Supply of Pheburane Amid Changes

Updated Category News Views 0

There's a breath of relief in the air over at Medunik USA, where they're keeping a steady course amidst some choppy waters. Those dealing with urea cycle disorders (UCD) have had their fair share of ups and downs, but Pheburane® isn’t going anywhere anytime soon. Medunik USA Holds the Line So, picture yourself in the shoes of a patient battling a rare urea cycle...

Continue Reading
RKD Groups' New Initiative: Monthly Giving Accelerator

Updated Category News Views 33

Something’s cooking in the nonprofit realm, and it ain’t business as usual. RKD Group is stirring the pot big time with their latest endeavor: the Monthly Giving Accelerator. They’ve roped in Dana Snyder, who’s got a track record working with big guns like the Canadian Red Cross and Movember. Let’s just say she's got a Ph.D. in monthly donations. What’s the...

Continue Reading
Definity Teams Up with Germany's dab for SAP Push in LATAM

Updated Category News Views 63

New Frontiers in SAP Integration Definity and dab are taking a pretty big step, folks. They're marching right into the SAP data integration game in Latin America, thanks to a fresh partnership. What you've got here is Mexican-based Definity teaming up with dab from Germany, the brains behind the dab Nexus platform. Bridging the Data Divide Here's the crux of the matter....

Continue Reading
Los Cabos Aims High: Luxury Tourism Plans for 2036

Updated Category News Views 0

Aiming for the Stars: Los Cabos' 2036 Tourism Vision When you talk about a place like Los Cabos, it's like watching someone polish a gem that's already gleaming. They've spent the past decade ramping up visitation, connectivity, and their tourism value, and now they're eyeing a bold new horizon. By 2036, they're not just hoping to lure in the good ol' luxury traveler. No,...

Continue Reading
AEP's $100B Power Plan: Investing in Tomorrow's Energy

Updated Category News Views 0

Electricity Powerhouse Unleashes Ambitious Plan If you thought American Electric Power (NASDAQ:AEP) was just cruising along, think again. This week, they rolled out an eye-popping $100 billion plan to supercharge their infrastructure and meet soaring electricity demands. It’s like they’re building the future of power right in front of our eyes. Third-quarter earnings...

Continue Reading
Qloo's AI Reveals Overlooked EV Market Opportunities

Updated Category News Views 99

Uncovering Surprising Market Overlaps Ever thought the guy barreling through mud in his rugged 4x4 might have more in common with an electric vehicle enthusiast than we'd usually guess? That's the curveball Qloo and Kearney are tossing at us. Their latest study shakes up the tired old assumptions floating around the automotive sector about who's buying what and why. Using...

Continue Reading
DexCom Faces Scrutiny: Fiduciary Breach Questioned

Updated Category News Views 239

Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...

Continue Reading
Set Hach: A Leader Transforming Agrifood Systems

Updated Category News Views 89

From Humble Beginnings to Global Recognition When a name like Set Hach doesn't just echo within local circles but reaches the global stage, you know something transformative is brewing. Here we have a woman celebrated as one of the 100 Women Heroes in Agrifood Systems by the UN Food and Agriculture Organization (FAO). Recognition like this speaks volumes, especially...

Continue Reading
Webull Faces Class Action: Deadline Looms Dec 2026

Updated Category News Views 48

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Partnership Between J-Stories and SusHi Tech 2025

Updated Category News Views 347

J-Stories Partners with SusHi Tech Tokyo 2025 J-Stories, a multilingual news service devoted to solutions-focused journalism, proudly announces its role as the official media partner for SusHi Tech Tokyo 2025. This esteemed event is recognized as Asia's largest startup conference and is poised to enhance its mission of promoting open innovation to tackle urban challenges...

Continue Reading
F5's Innovative AI Solutions Transform Kubernetes for Enterprises

Updated Category News Views 262

Leveraging Advanced AI Capabilities with F5 and NVIDIA Today, F5 (NASDAQ: FFIV) made a significant stride in the field of AI application delivery and security for both service providers and enterprises. With the launch of BIG-IP Next for Kubernetes, organizations now have a powerful solution designed to streamline data traffic and enhance security for AI-driven...

Continue Reading
Bill Gates Responds to Lyft CEO's Bold Move to Amazon

Updated Category News Views 189

Bill Gates Critiques Lyft CEO Risher on His Amazon Decision David Risher, the visionary leader behind Lyft Inc. (NASDAQ: LYFT), recently discussed a pivotal career choice from his past that prompted criticism from none other than Bill Gates, co-founder of Microsoft Corp. (NASDAQ: MSFT). In a revealing podcast session, Risher shared insights into this defining moment...

Continue Reading
Sunoco LP to Announce Q1 2025 Gains and Upcoming Call

Updated Category News Views 417

Sunoco LP Earnings Overview for 2025 Sunoco LP (NYSE: SUN) has emerged as a significant player in the energy and fuel distribution sector. Its upcoming announcement regarding the first-quarter earnings release is generating a lot of anticipation among investors and analysts alike. Scheduled for release before market opening on the designated day, this report is expected...

Continue Reading
Waste Management's P/E Ratio: Insights for Investors

Updated Category News Views 286

Understanding Waste Management's Stock Performance Currently, Waste Management Inc. (NASDAQ: WM) is trading at $229.17, reflecting a modest increase of 0.21%. Over the last month, the stock has demonstrated a growth of 3.36%, and over the past year, it has appreciated by 11.72%. This strong performance has instilled a sense of optimism among long-term shareholders,...

Continue Reading